Yüklüyor......
Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
Recent analyses by our group and others showed that the majority of melanoma patients who fail BRAF inhibitor therapy do so at new disease sites. Using phosphoproteomics we showed that BRAF inhibition mediates a switch to an aggressive/metastatic melanoma phenotype that is driven by ligand-independe...
Kaydedildi:
| Yayımlandı: | Mol Cell Oncol |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Taylor & Francis
2015
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4905349/ https://ncbi.nlm.nih.gov/pubmed/27308505 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/23723556.2015.1008291 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|